MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance

Clinical Cancer Research

Volumn 15, Issue 14, 2009, Pages 4622-4629

  Yip, Stephen ^a,b   Miao, Jiangyong ^a,b   Cahill, Daniel P ^a   Iafrate, A John ^a,b   Aldape, Ken ^c   Nutt, Catherine L ^a,b   Louis, David N ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN MSH6; SHORT HAIRPIN RNA; TEMOZOLOMIDE;

ALKYLATION; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DRUG RESISTANCE; GENE EXPRESSION; GENE FUNCTION; GENE INACTIVATION; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MICROSATELLITE INSTABILITY; MOLECULAR CLONING; PHENOTYPE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, ALKYLATING; BASE SEQUENCE; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; DACARBAZINE; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GLIOBLASTOMA; HUMANS; MICROSATELLITE INSTABILITY; MUTATION; RNA INTERFERENCE; TUMOR CELLS, CULTURED;

EID: 68049095262     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-3012     Document Type: Article

References (37)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-996 (Pubitemid 40349501)
2. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003. (Pubitemid 40349502)
3. Hau P, Stupp R, Hegi ME. MGMT methylation status: the advent of stratified therapy in glioblastoma? Dis Markers 2007;23:97-104.
4. Bondy ML, Scheurer ME, Malmer B, et al. Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer 2008;113:1953-1968
5. Louis DN. Molecular pathology of malignant gliomas. Annu Rev Pathol 2006;1:97-117.
6. Sarkaria JN, Kitange GJ, James CD, et al. Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res 2008;14:2900-2908
7. Hunter C, Smith R, Cahill DP, et al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res 2006;66:3987-3991
8. Kat A, Thilly WG, Fang WH, Longley MJ, Li GM, Modrich P. An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. Proc Natl Acad Sci U S A 1993;90:6424-6428 (Pubitemid 23207225)
9. Umar A, Koi M, Risinger JI, et al. Correction of hypermutability, N-methyl-N′-nitro-N-nitrosoguanidine resistance, and defective DNA mismatch repair by introducing chromosome 2 into human tumor cells with mutations in MSH2 and MSH6. Cancer Res 1997;57:3949-3955
10. Levati L, Marra G, Lettieri T, et al. Mutation of the mismatch repair gene hMSH2 and hMSH6 in a human T-cell leukemia line tolerant to methylating agents. Genes Chromosomes Cancer 1998;23:159-166 (Pubitemid 28402342)
11. Hickman MJ, Samson LD. Apoptotic signaling in response to a single type of DNA lesion, O (6)-methylguanine. Mol Cell 2004;14:105-116
12. Allan JM, Travis LB. Mechanisms of therapy-related carcinogenesis. Nat Rev Cancer 2005;5:943-955
13. Cahill DP, Levine KK, Betensky RA, et al. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res 2007;13:2038-2045
14. TCGA Consortium. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-1068
15. Maxwell JA, Johnson SP, McLendon RE, et al. Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma. Clin Cancer Res 2008;14:4859-4868
16. Loukola A, Eklin K, Laiho P, et al. Microsatellite marker analysis in screening for hereditary nonpolyposis colorectal cancer (HNPCC). Cancer Res 2001;61:4545-4549 (Pubitemid 32685787)
17. Sena-Esteves M, Tebbets JC, Steffens S, Crombleholme T, Flake AW. Optimized large-scale production of high titer lentivirus vector pseudotypes. J Virol Methods 2004;122:131-139 (Pubitemid 39470183)
18. Kock N, Kasmieh R, Weissleder R, Shah K. Tumor therapy mediated by lentiviral expression of shBcl-2 and S-TRAIL. Neoplasia 2007;9:435-442 (Pubitemid 46799987)
19. Jiricny J. The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol 2006;7:335-346
20. Berends MJ, Wu Y, Sijmons RH, et al. Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant. Am J Hum Genet 2002;70:26-37. (Pubitemid 34031695)
21. Gombar CT, Tong WP, Ludlum DB. Mechanism of action of the nitrosoureas-IV. Reactions of bischloroethyl nitrosourea and chloroethyl cyclohexyl nitrosourea with deoxyribonucleic acid. Biochem Pharmacol 1980;29:2639-2643
22. Goerne R, Bogdahn U, Hau P. Procarbazine - a traditional drug in the treatment of malignant gliomas. Curr Med Chem 2008;15:1376-1387 (Pubitemid 351997788)
23. Clark AB, Deterding L, Tomer KB, Kunkel TA. Multiple functions for the N-terminal region of Msh6. Nucleic Acids Res 2007;35:4114-4123 (Pubitemid 47244632)
24. Yang G, Scherer SJ, Shell SS, et al. Dominant effects of an Msh6 missense mutation on DNA repair and cancer susceptibility. Cancer Cell 2004;6:139-150 (Pubitemid 39485686)
25. Wu Y, Berends MJ, Mensink RG, et al. Association of hereditary nonpolyposis colorectal cancer-related tumors displaying low microsatellite instability with MSH6 germline mutations. Am J Hum Genet 1999;65:1291-1298 (Pubitemid 30460379)
26. Verma L, Kane MF, Brassett C, et al. Mononucleotide microsatellite instability and germline MSH6 mutation analysis in early onset colorectal cancer. J Med Genet 1999;36:678-682 (Pubitemid 29433725)
27. Martomo SA, Yang WW, Gearhart PJ. A role for Msh6 but not Msh3 in somatic hypermutation and class switch recombination. J Exp Med 2004;200:61-68 (Pubitemid 38924728)
28. Slean MM, Panigrahi GB, Ranum LP, Pearson CE. Mutagenic roles of DNA "repair" proteins in antibody diversity and disease-associated trinucleotide repeat instability. DNA Repair (Amst) 2008;7:1135-1154
29. Friedberg EC. How nucleotide excision repair protects against cancer. Nat Rev Cancer 2001;1:22-33.
30. Silber JR, Bobola MS, Ghatan S, Blank A, Kolstoe DD, Berger MS. O6-methylguanine-DNA methyltransferase activity in adult gliomas: relation to patient and tumor characteristics. Cancer Res 1998;58:1068-1073 (Pubitemid 28182481)
31. 6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 2005;23:7178-7187
32. 6- methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 2008;26:4189-4199
33. Liu L, Markowitz S, Gerson SL. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl) nitrosourea. Cancer Res 1996;56:5375-5379 (Pubitemid 27011367)
34. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343:1350-1354 (Pubitemid 30826035)
35. Koch D, Hundsberger T, Boor S, Kaina B. Local intracerebral administration of O (6)-benzylguanine combined with systemic chemotherapy with temozolomide of a patient suffering from a recurrent glioblastoma. J Neurooncol 2007;82:85-89
36. Alvino E, Castiglia D, Caporali S, et al. A single cycle of treatment with temozolomide, alone or combined with O (6)-benzylguanine, induces strong chemoresistance inmelanoma cell clones in vitro: role of O (6)-methylguanine-DNA methyltransferase and the mismatch repair system. Int J Oncol 2006;29:785-797
37. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807-1812